↓ Skip to main content

Acute interstitial nephritis after sequential ipilumumab - nivolumab therapy of metastatic melanoma

Overview of attention for article published in Journal for Immunotherapy of Cancer, July 2017
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (55th percentile)

Mentioned by

twitter
4 tweeters

Citations

dimensions_citation
23 Dimensions

Readers on

mendeley
48 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Acute interstitial nephritis after sequential ipilumumab - nivolumab therapy of metastatic melanoma
Published in
Journal for Immunotherapy of Cancer, July 2017
DOI 10.1186/s40425-017-0261-2
Pubmed ID
Authors

Lea Bottlaender, Anne-Laure Breton, Louis de Laforcade, Frederique Dijoud, Luc Thomas, Stephane Dalle

Abstract

The anti-Programmed Death receptor 1 (anti-PD-1) antibodies nivolumab and pembrolizumab are new treatments in metastatic melanoma. Immunotherapies are best known to be responsible for thrombotic microangiopathy. However, immune interstitial nephritis has been described in a patient treated by nivolumab and ipilimumab concomitantly, and three cases of granulomatous interstitial nephritis have been reported with ipilimumab monotherapy. We report herein a case of acute interstitial immune nephritis in a patient treated with nivolumab after ipilimumab for pulmonary metastatic melanoma. Interstitial nephritis was diagnosed after acute kidney injury following three cycles and was confirmed by kidney biopsy. Kidney injury responded rapidly to prednisolone, which was then gradually reduced. As a follow-up computed tomography scan indicated mixed response, with minimal size progression of a pulmonary nodule, but a significant reduction in the size of the other nodules, nivolumab was reintroduced after renal function improvement. Low-dose corticosteroids were first maintained during nivolumab treatment and subsequently discontinued. Only one month after prednisolone discontinuation, creatinine levels increased. A second kidney biopsy confirmed relapse of acute interstitial nephritis. To our knowledge, this is the first case of nivolumab-induced acute interstitial immune nephritis. This case highlights that anti-PD-1 immunotherapy may be continued when renal function is adequate, and this requires close interaction between dermatologists and nephrologists. This adverse effect should be made known to prescribers as nivolumab is associated with significant improvement of survival in metastatic melanoma and may be used in many different types of cancer.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 48 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 48 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 10 21%
Researcher 9 19%
Student > Bachelor 6 13%
Other 6 13%
Student > Postgraduate 3 6%
Other 7 15%
Unknown 7 15%
Readers by discipline Count As %
Medicine and Dentistry 25 52%
Pharmacology, Toxicology and Pharmaceutical Science 3 6%
Biochemistry, Genetics and Molecular Biology 2 4%
Immunology and Microbiology 2 4%
Business, Management and Accounting 1 2%
Other 4 8%
Unknown 11 23%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 August 2017.
All research outputs
#9,644,586
of 17,608,563 outputs
Outputs from Journal for Immunotherapy of Cancer
#1,174
of 1,777 outputs
Outputs of similar age
#120,217
of 274,043 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#1
of 1 outputs
Altmetric has tracked 17,608,563 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,777 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.8. This one is in the 32nd percentile – i.e., 32% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 274,043 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 55% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them